Shanna Brown, MD
Ophthalmology · McAllen, TXNPI 1467613513
Payments from drug & device makers
Across 121 payments — averaging $37.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$521
- Biotissue Holdings Inc.$385
- Bausch & Lomb Americas Inc.$374
- Alcon$303
- Glaukos Corporation$284
- Apellis Pharmaceuticals, Inc.$228
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,509100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $521 |
| Biotissue Holdings Inc. | 6 | $385 |
| Bausch & Lomb Americas Inc. | 17 | $374 |
| Alcon | 4 | $303 |
| Glaukos Corporation | 3 | $284 |
| Apellis Pharmaceuticals, Inc. | 2 | $228 |
| Rxsight Inc | 3 | $224 |
| Novartis | 12 | $194 |
| Sight Sciences, Inc. | 5 | $191 |
| Kala Pharmaceuticals, Inc. | 4 | $172 |
| Tarsus Pharmaceuticals, Inc. | 3 | $171 |
| Astellas Pharma US Inc | 1 | $150 |
| Coherus Oncology, Inc. | 1 | $149 |
| Genentech USA, Inc. | 2 | $142 |
| Tearlab Corp | 1 | $133 |
| Regeneron Healthcare Solutions, Inc. | 1 | $126 |
| Dompe US, Inc. | 1 | $125 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $121 |
| Biogen | 1 | $91 |
| Oyster Point Pharma, Inc. | 4 | $88 |
| Ocular Therapeutix, Inc. | 4 | $80 |
| Mallinckrodt Hospital Products Inc. | 3 | $74 |
| Eyevance Pharmaceuticals LLC | 2 | $40 |
| Sun Pharmaceutical Industries Inc. | 2 | $37 |
| Mallinckrodt Enterprises LLC | 1 | $32 |
| Merz North America, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $18 |
| GSK | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Syfovre$228
- Cimerli$149
- Clareon$144
- CE-marked KXLA system$134
- TearLab Osmolarity System$133
- OMNI(R) SURGICAL SYSTEM (US)$128
- EYLEA$126
- XDEMVY$125
- Oxervate$125
- INVELTYS$124
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$122
- IACCESS$116
- iStent inject W$116
- KXL System$116
- Photrexa$116
- VABYSMO$115
- VYZULTA$115
- DURYSTA$103
- OZURDEX$103
How this compares
$4,509 in reported general payments places this provider in the 70th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 1,509 | $63,600 |
| RestasisCyclosporine | 55 | $47,985 |
| LumiganBimatoprost | 83 | $37,923 |
| XiidraLifitegrast | 24 | $31,233 |
| MoxifloxacinMoxifloxacin Hcl | 837 | $23,750 |
| VyzultaLatanoprostene Bunod | 49 | $19,344 |
| Ketorolac Tromethamine | 611 | $17,445 |
| CombiganBrimonidine Tartrate/Timolol | 36 | $9,700 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $6,610 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 24 | $4,999 |
| Latanoprost | 459 | $4,698 |
| Brimonidine Tartrate | 164 | $4,095 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 32 | $4,058 |
| Ofloxacin | 210 | $2,530 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 103 | $1,624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $521 | $95,608174 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $374 | $50,57773 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $14 | $6,61013 claims |
| AlconSimbrinza | $303 | $4,99924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in McAllen
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Patrick WilliamsArlington$6.6M
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Michael SingerSan Antonio$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.